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CHALLENGES IN 
DEVELOPMENT AN anti-
IDIOTYPIC CANCER 
VACCINE
Adolfo J. Castillo Vitlloch
Early Stage Product Development | VACCINE TECHNOLOGY IVAlbufeira, Portugal, May 2012
GANGLIOSIDE TARGETED IMMUNOTHERAPY
 A scientific discovery in 1996: Ganglioside-
pattern expressed in human breast cancer
(Marquina et al., Cancer Res 1996, 
56(22):5165-5171)
 N-glycolylneuraminic acid-containing 
gangliosides are attractive targets for 
FAB mass spectra of NGcGM3 
isolated from tumor samples
:  N-glycolyl GM3OH
H :  N-acetyl GM3R
R
cancer immunotherapy because these 
glycolipids are non-self antigens in humans 
(Irie et al., J Biol Chem 1998, 
273(25):15866-15871)
 Recent experimental data suggest that N-
glycolyl-GM3 ganglioside is relevant for 
tumor biology (de Leon et al., Cancer 
Immunol Immunother 2006, 55(4):443-450)
An emerging concept: N-glycolylated
gangliosides are Tumor Specific Antigens and 
Idiotypic Network Antigens
TWO NOVEL THERAPEUTIC APPROACHES
 Racotumomab is an IgG1 anti-idiotype
(Ab2) mAb obtained by immunizing 
- Hydrophobically incorporated gangliosides into bacteria-derived 
proteosomes
- Anti-idiotypic monoclonal antibodies as antigen surrogates 
Ab3
antigen specific
Balb/c mice with Ab1 coupled to 
keyhole limpet hemocyanin (KLH) in the 
presence of Freund’s adjuvant
 Racotumomab (Ab2) behaves as an 
antigen internal image of antigen: 
immune networks discriminates self 
versus non-self
Vazquez et al., Hybridoma 1995, 14(6):551-556
Vazquez et al., Hybridoma 1998, 17(6):527-534.
Tumor 
associated
antigen
Ab1
Ab2
(Racotumomab)
ANTIMETASTATIC EFFECT AND APOPTOSIS INDUCTION 
BY RACOTUMOMAB IV TREATMENT IN 3LL-D122 
TUMOR MODEL
Alfonso et al., Cancer Biology & Therapy, 2007
PBS ior C5 Raco-
tumomab
Fuentes et al., Breast Cancer Res Treat 2009
1E10/Al PBS/AlC5/Al
Diaz et al., Cancer Immunol Immunother 2009, 58(7):1117-1128
Apoptosis was measured by 
the Apoptag system methods
135/174 patients (77,5%)
Only patients who completed the induction period
of the study (> 5 doses) were included in this
analysis
PHASE II/III CLINICAL TRIAL IN NSCLC
Multicentric, randomized, double blind and placebo- controlled
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Log rank test : p= 0.0023
OS Analysis
Other Raco Clin. Trials reports: Alfonso et al., J Immunol 2002, 168(5):2523-2529; Diaz et al., Clin Immunol 2003, 107(2): 
80-89; Neninger et al., Cancer Biol Ther 2007, 6(2):145-150; Hernandez et al., J Immunol 2008, 181(9):6625-6634.
OS (PPP)
Group Median, months
Vaccine (n=70) 10.90 (95% CI 6.82 -14.98 ) 
Placebo (n= 65) 6.90  (95% CI 4.43 –9.37 ) 
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Racotumomab
Placebo
Kaplan-Meier survival curves in relation to
treatment. Per Protocol Analysis, ≥5 doses 
(induction phase)
A MONOCLONAL ANTIBODY AS ANTIGEN: FROM 
ASCITIS TO BIOREACTOR
Stirred Tank
15 L, protein free 
medium
Raco supernatant
Murine Ascitis
Fluid
Protein A chromatography
Ionic exchange chromatography
Ionic exchange chromatography
Protein A chromatography
Raco AF Raco ST
Both products have the same molecular mass for whole 
antibody molecule obtained by SDS-PAGE
MALDI-TOF-TOF in linear mode 
Stirred tank 
fermentation 
(Raco ST)
Mice Ascitis 
(Raco AF)
Mice Ascitis
B
(Raco AF)
LC-ESI-QTOF MS-MS
Both molecules have the same “peptide mass fingerprinting”
pattern indicating high similarity
Raco AF
Raco ST
The amino acid sequence, N-terminal pyroglutamic acid, Asn 
glycosylation and three deamidation sites are common for both 
conditions, while oxidized methionine found only in Raco-ST
Modifications Raco AF Raco ST
N-term Gln to 
pyroglutamic
acid
+ +
Glycosilation
of Asn
+ +
MALDI TOF MS/MS
Raco ST
Machado et al. BMC Biotechnology 2011, 11:112
294
Deamidation
of Asn141 (CH)
+ +
Deamidation
of Asn157 (CL)
+ +
Deamidation
of Asn161 (CL)
+ +
Oxidation of 
Met396
- +
+ Modified; - Non modified
Raco AF
Very low amounts of aggregates in Raco-AF and ST, but
low molecular weight fragments present only in Raco-AF
HPSEC (TSK G2000 
WXL in HPI100)
UV detector at 280 nm, 
sequential refractive
index (RI), intrinsic 
viscosity (IV), and 
Raco STHPSEC-TDA
Refractive index
Log MW
150 kD
Log Radius
300 kD
Machado et al. BMC 
Biotechnology 2011, 
11:112
right-angle light 
scattering detection 
(TDA 302, Viscotek 
Corp.)
Raco AF
Rigth angle ligth scattering
150 kD
75 kD
Slightly more acidic isoelectric point of Raco-ST and different 
charge profile compared with Raco-AF, even after C-terminal 
lysine removal
WCX-HPLC
Machado et al. BMC Biotechnology 2011, 11:112
Raco ST
Raco AF
ST  AF MW std
Same sugar structures attached to Fc of Raco-AF and ST 
(mainly fucosilated, not bisected in N-acetilglucosamine, 
mostly G0 and G1 estructures); but not their relative amount
Raco AF
MALDI TOF/TOF
HPLC glycan amide
profile
Machado et al. BMC Biotechnology 2011, 11:112
Raco ST
Raco 
AF
Raco 
ST
Raco FA and ST have similar Ab1 recognition profile and 
deglycosilation with PNGase F didn’t affect specific activity
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p > 0,05
Ab1
Racotumomab 
(Ab2)
Anti mouse IgG1
Phosphatase 
conjugated
Test One-
Way Anova
Log Mab Conc.
Raco AF
Raco ST
Native 
Raco ST
Deglycosilated 
Raco ST
Denatured 
Raco ST
GROUPS
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DO Ab1 recognition 
DO isotype (IgG1) recognition
The presence of phosphate ion in vaccine formulation affects 
the adsorption for pH values above 7, even when ionic 
strength is increased
pH pH Phosphate
24 months 
stability
12 months 
stability
Adsorption 
Raco Mab/ 
Alumina, 
% 
Increases in phosphate concentration and buffer pH rendered 
alumina more negatively charged, while Racotumomab 
became negative when pH increases above 6
Phosphate
Zp of alumina in different buffers Zp of Racotumomab in different buffers
The presence of phosphate decreased the adsorption due to electrostatic repulsion and  
inhibit the anion ligand exchange of carboxyl groups of the mAb with the alumina.
pH
+11,8
- 7,95
To use Alumina/TRIS at pH8 in the Racotumomab ST vaccine formulation
New proposed formulation for Raco ST based on Alumina/ 
TRIS, pH8 showed lower median particles size than RacoAF/ 
Alumina/Phosphate buffer, pH 7 despite very low value of Zp
Alum./Phosphate 
buffer, pH 7
Alum./TRIS buffer, pH 8 1500
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Alumina, pH7
Phosphate
Alumina, pH8
TRIS
Raco AF
Raco ST
Electrostatic interaction plays a minor role on adsorption, but the ligand exchange reaction 
may be responsible of the  stronger interaction between Racotumumab and alumina.
Zp, mV
Raco AF/Alum./ 
Phosphate, pH 7
Raco ST/Alum./TRIS, pH 8
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Racotumomab/adjuvant ratio didn´t affect immunogenicity in 
chickens measured as the antibody titers against antigen, both 
IgG1 isotypic and idiotypic response 
vs. Racotumomab
Bleeding
0 14 217
Inmunization
Day
Test One-Way Anova
Raco ST, Raco AF or 
isotype control
Sera from 
immunized 
chicken
Rabbit anti IgY-
AP conjugated
To maintain 5 mg/mL of alumina in the vaccine formulation
5 2,5 0,5 0 AF 5
Raco ST
5 2,5 0,5 0 AF 5
Raco ST
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mg/mL 
AlOH
Similar Ab3 antibody responses elicited by Raco-AF and
ST vaccination in chicken
22/22 100 %
20/21 95%
Frequency of  seroconversion  
to NGcGM3
Bleeding
0 14 217
Inmunization
Day
Machado et al. BMC Biotechnology 2011, 11:112
RacoC5
Idiotypic 
dominance
Raco ST, Raco AF or 
isotype control
Sera from 
immunized 
chicken
Rabbit anti IgY-
AP conjugated
Co-administration of Raco-AF/Alum or Raco ST/Alum with
low-dose Cyclophosphamide induced anti-tumor effects
in a mammary carcinoma model
Control
Raco ST/Alum
Cy-150+Raco AF/Alum
Machado et al. BMC Biotechnology 2011, 11:112
Dox + Cy-600
Cy-150+Raco ST/Alum
Days after tumor inoculation
Log Rank 
Log Rank 
p= 0.49
Expanded  Access Program (Population-based study) in 
patients with advanced stages (IIIB/IV) of NSCLC 
(recurrent and/ or metastatic)
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Funciones de supervivencia
Survival functions
Intent  to Treat. Per protocol: ≥ 5doses
Treated group Treated group
Raco AF
Raco ST
Raco AF censured
Raco ST cens re  
Raco AF
Raco ST
Raco AF censured
Raco ST censured 
Raco ST
P= 0.77
OS (ITT)
Group Mean
months
Median
months
SV
rate 
12m
SV 
rate 
24 m
Raco ST
N= 180, E= 132 16.6 8.06 39 21
Raco AF
N= 89 E= 73 15.6 8.26 38 17
OS per protocol
Group Mean
months
Median
months
SV
Rate
At 12m
SV 
Rate at 
24m
Raco ST
N= 124, E= 81 19.3 12.1 55 38
Raco AF
N= E= 20.2 13.1 53 21.7
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CONCLUSIONS
 Here, we demonstrate that change of Racotumomab production from 
ascites to bioreactor generates a molecule with a high similarity of 
point of view of primary structure, but with some different 
physicochemical properties. 
 Changes were observed in the degree of asparagine deamidation, C-
terminal, lysine processing, methionine oxidation, and glycosylation 
pattern, that had an impact on the charge profile of the Mab 
molecule.
 Removal of phosphate and use of TRIS buffer at pH 8, maintaining 5 
mg/mL of Alumina concentration in Racotumomab ST vaccine 
formulation allowed a higher and more stable adsorption level.
 No aggregates or increase in particle size were observed despite the 
low values of Z potential obtained with the new formulation.
CONCLUSIONS
 However, observed changes did not affected the biological activity of 
the product, i.e. the idiotypic dominance (which represents the intended 
effect for an idiotypic vaccine) and the antitumoral effect in mice.
 Moreover clinical evaluation of vaccine based on Racotumomab 
produced by in vitro process confirmed results obtained using bio-
models and were comparable with those obtained using in vivo based
production process.
 Furthermore, our study demonstrated a number of physicochemical 
properties that do not affect the biological activity of the idiotypic 
vaccine, and by consequence should not be considered as critical 
attributes.
 Thus, the transfer of production process of idiotypic mAb from ascites to 
bioreactor improved product safety, without affecting its biological 
activity. 
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